Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Bayer Looks To Singapore To Develop Cancer Drugs For Asian Patients

This article was originally published in PharmAsia News

Executive Summary

NEW DELHI - Bayer Schering Pharma Asia Pacific, a unit of Germany-based Bayer Schering Pharma AG, and the Yong Loo Lin School of Medicine of the National University of Singapore will team up to develop novel cancer-fighting drugs targeted specifically at Asian patients

You may also be interested in...

Bayer Gains China’s Go-Ahead To Sell Liver Cancer Drug Nexavar In World’s Biggest Potential Market

BEIJING - After receiving regulatory approval to sell the liver cancer drug Nexavar in China, executives at Bayer HealthCare Pharmaceuticals indicated the country could become the biggest market in the world for the compound

Pfizer Head of R&D Business Development-Asia Alex Fowkes On Developing R&D Strategies For Asia: An Interview With PharmAsia News (Part 1 of 2)

Pfizer Head of R&D Business Development-Asia Alex Fowkes sat down recently with PharmAsia News' Australia bureau to discuss Pfizer's research and business development strategies in Asia. Fowkes recently addressed a panel at the BioAsia conference in Singapore and discussed Pfizer's virtual networking approach to doing business in Asia, which offers more flexibility and creative approaches (PharmAsia News, May 8, 2008).

PharmAsia News Business Bulletin

A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts